The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study
Abstract
Objective. To examine the effects of cyclophosphamide (CYC) on the development of malignancies and on the long‐term survival of patients with rheumatoid arthritis (RA). Methods. We used a longitudinal cohort design in which 119 patients (76 women and 43 men) with refractory RA who were treated with oral CYC between 1968 and 1973 were compared with 119 control patients with RA (matched for age, sex, disease duration, and functional class) who were evaluated during the same time period but did not receive CYC. Results. There was increased risk of malignancy in the CYC‐treated group, with 50 cancers found in 37 patients in the CYC group compared with 26 cancers in 25 of the control patients (P < 0.05). The relative risk of cancer for those treated with CYC was 1.5 (95% confidence interval 0.93–5.5). Nine of the malignancies in the CYC group were bladder cancers and 19 were skin cancers, compared with no bladder cancers and 6 skin cancers in the control group. The total dose of CYC was higher in those who developed cancer, particularly in those with bladder cancer. Three of the bladder cancers occurred 14, 16, and 17 years after CYC had been discontinued. Conclusion. The risk of malignancy, particularly bladder cancer, in RA patients treated with oral CYC continues even 17 years after discontinuation of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
STEINBROCKER, O. (1949) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1949.02900430001001 · Cited by 2,877
Wegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Incidence of Cancer Among Patients With Rheumatoid Arthritis
Gridley, G., McLaughlin, J. K., Ekbom, A., Klareskog, L., Adami, H.-O., Hacker, D. G., Hoover, R., & Fraumeni, J. F. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.307 · Cited by 581
Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis
Fauci, A. S., Katz, P., Haynes, B. F., & Wolff, S. M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908023010503 · Cited by 526
Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
Isomäki, H. A., Hakulinen, T., & Joutsenlahti, U. (1978) · Journal of Chronic Diseases · doi:10.1016/0021-9681(78)90071-1 · Cited by 433
Leukemia After Therapy With Alkylating Agents for Childhood Cancer2
Tucker, M. A., Meadows, A. T., Boice, J. D., Stovall, M., Oberlin, O., Stone, B. J., Birch, J., Voûte, P. A., Hoover, R. N., Fraumeni, J. F., et al. (1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/78.3.459 · Cited by 352
Cyclophosphamide-induced hemorrhagic cystitis: A review of 100 patients
Stillwell, T. J., & Benson, R. C. (1988) · Cancer · doi:10.1002/1097-0142(19880201)61:3<451::aid-cncr2820610308>3.0.co;2-g · Cited by 304
Silman, A. J., Petrie, J., Hazleman, B., & Evans, S. J. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.12.988 · Cited by 276
(1970) · New England Journal of Medicine · doi:10.1056/nejm197010222831701 · Cited by 214
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Jabs, D. A., Rosenbaum, J. T., Foster, C. S., Holland, G. N., Jaffe, G. J., Louie, J. S., Nussenblatt, R. B., Stiehm, E. R., Tessler, H., Van Gelder, R. N., et al. (2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00659-0 · Cited by 995
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22864 · Cited by 534
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
Metadata
- Authors
- Radis, C. D., Kahl, L. E., Baker, G. L., Wasko, M. C. M., Cash, J. M., Gallatin, A., Stolzer, B. L., Agarwal, A. K., Medsger, T. A., & Kwoh, C. K.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1995-08
- Volume
- 38
- Issue
- 8
- Pages
- 1120-1127
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2140216003
- Cited by
- 314
- References
- 18
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study. https://app.cochat.ai/papers/10.1002/art.1780380815
- The paper
- Radis, C. D., Kahl, L. E., Baker, G. L., Wasko, M. C. M., Cash, J. M., Gallatin, A., Stolzer, B. L., Agarwal, A. K., Medsger, T. A., & Kwoh, C. K. (1995). Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study. Arthritis & Rheumatism. https://doi.org/10.1002/art.1780380815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.